Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protein degradation technology: a strategic paradigm shift in drug discovery
Haobin Li, Jinyun Dong, Mao-Hua Cai, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic
Janet M. Sasso, Rumiana Tenchov, Dasheng Wang, et al.
Biochemistry (2022) Vol. 62, Iss. 3, pp. 601-623
Open Access | Times Cited: 96
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 46
Focal adhesion kinase: from biological functions to therapeutic strategies
Ximin Tan, Yuheng Yan, Bin Song, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Yingxu Fang, Jiaxing Wang, Min Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11454-11477
Closed Access | Times Cited: 44
Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively
Kanak Raina, Chris D. Forbes, Rebecca Stronk, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 26
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 23
Regulated induced proximity targeting chimeras—RIPTACs—A heterobifunctional small molecule strategy for cancer selective therapies
Kanak Raina, Chris D. Forbes, Rebecca Stronk, et al.
Cell chemical biology (2024) Vol. 31, Iss. 8, pp. 1490-1502.e42
Closed Access | Times Cited: 9
Inhibitors to degraders: Changing paradigm in drug discovery
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 6
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access
Bacteroides Fragilis Transplantation Reverses Reproductive Senescence by Transporting Extracellular Vesicles Through the Gut‐Ovary Axis
Yan Xiong, Xiaoxue Lu, Bohao Li, et al.
Advanced Science (2025)
Open Access
Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies
Yu‐meng Ji, Baixue Li, Rongjin Lin, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
PROTACs coupled with oligonucleotides to tackle the undruggable
Guangshuai Zhang, Si Yan, Yan Liu, et al.
Bioanalysis (2025), pp. 1-16
Closed Access
Targeted protein degraders march towards the clinic for neurodegenerative diseases
Dhiraj Kumar, Md. Imtaiyaz Hassan
Ageing Research Reviews (2022) Vol. 78, pp. 101616-101616
Closed Access | Times Cited: 28
Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities
Pritam Maity, Joydeep Chatterjee, Kiran T. Patil, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 5, pp. 3135-3172
Closed Access | Times Cited: 18
DNA framework-engineered chimeras platform enables selectively targeted protein degradation
Li Zhou, Bin Yu, Mengqiu Gao, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115741-115741
Closed Access | Times Cited: 17
Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4
Mao-Hua Cai, Furong Ma, Can Hu, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 90, pp. 117352-117352
Closed Access | Times Cited: 15
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Xian-Miao Li, Zhenyu Zhao, Yu Xiao, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 14
New implications for prion diseases therapy and prophylaxis
Fangzhou Liu, Wenqi Lü, Ling Liu
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 4
An updated patent review of BRD4 degraders
Zonghui Ma, Cun Zhang, Andrew A. Bolinger, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 929-951
Closed Access | Times Cited: 4
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Yanhong Ni, Jun T. Low, John Silke, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Sinan Ma, Jianai Ji, Yuanyuan Tong, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 2990-3005
Open Access | Times Cited: 23
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 11
Research progress of PROTACs for neurodegenerative diseases therapy
Zhifang Cai, Zunhua Yang, Huilan Li, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107386-107386
Closed Access | Times Cited: 3
Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis
Jinyun Dong, Furong Ma, Mao-Hua Cai, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 16712-16736
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top